At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 22 enrolled
Drug / intervention
Teriparatide (PTH 1-34)drug
Likely dose
Teriparatide (PTH 1-34) 20 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
In Brief
A Phase 3 clinical trial evaluating Teriparatide (PTH 1-34) for Menopause and 2 related conditions. Completed, enrolled 22 participants across 2 sites.
Detailed Summary
Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young individuals sustain one or more low-trauma fractures. Teriparatide \[PTH(1-34)\], which is FDA approved for treatment of osteoporosis in men and postmenopausal women, works by stimulating bone formation. The investigators hypothesize that teriparatide will significantly increase bone density (BMD) and improve bone structure in premenopausal women with IOP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopause, Fracture, Osteoporosis
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartAug 2008
Primary CompletionJan 2012
TodayJul 2026
First PostedJun 13, 2008
Enrollment StartAug 20, 2008
Primary CompletionJan 3, 2012
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 18.1 years ago
Interventions
Teriparatide (PTH 1-34)drug
20 micrograms subcutaneous injection daily